Lesinurad approved by the US FDA in December 2015. This study assess the
efficacy and safety of the combination of lesinurad and allopurinol in gout
patients who are non-responsive to allopurinol alone using meta-analysis
Search performed in multiple databases from inception to May 2019.
Double-blinded RCTs of lesinurad in combination with allopurinol versus
allopurinol alone were applied. Three studies, 922 patients met our inclusion
criteria. The primary outcome was the number of subjects achieving a serum
urate level <6.0 mg/dL at any follow-up point; the secondary endpoints were
the number of tophi with complete resolution; any reported gout flares, any
serious adverse events, withdrawal, or death.
relative risk showed a significant reduction in serum urate levels <6 mg/dL
in lesinurad 400mg group versus the allopurinol alone group (RR=2.51, 95%
CI=2.12- 2.98). Two studies reported reductions in gout flares between the
groups (RR=-0.07, 95%CI=-0.08 --0.05). The lesinurad group showed higher
serious adverse events when compared with allopurinol alone (RR=1.87,
Lesinurad 400mg in combination with allopurinol showed significant reduction in
urate levels <6 mg/dL and in number of gout flares. However, there were
higher AEs with the combination therapy of lesinurad and allopurinol.
review, Meta-analysis, Lesinurad, Gout, Allopurinol